Skip to main content

Table 1 Characteristics of the subjects who donated fibroblast-like synoviocytes for this study

From: Different expression of β subunits of the KCa1.1 channel by invasive and non-invasive human fibroblast-like synoviocytes

Donor

Diagnosis

Sex

Ethnicity

Disease duration (years)

RF

Medications

Origin of cells

Figures showing which cells were useda

RA-1

RA

Female

White

3

+

NSAID

Asterand Bioscience

1a, b; 2a, b; 3a, b, d

RA-2

RA

Male

Hispanic

<1

+

Prednisone, DMARD

Asterand Bioscience

2a, b; 5a, b, c; 6b

RA-3

RA

Female

White

<1

+

NSAID

Asterand Bioscience

2a, b; 3a, b, d

RA-4

RA

Female

White

12

+

NSAID, prednisone

Asterand Bioscience

1a, b; 2a, b; 4c

RA-5

RA

Female

Hispanic

2

+

DMARD, NSAID

FITDP

1a, b; 4a, b, e, f, g; 5a, b, c

RA-6

RA

Female

White

21

+

Prednisone, DMARD

FITDP

3a, b, c, d

RA-7

RA

Female

White

30

+

Prednisone, DMARD

FITDP

2a, b; 3a, b, c, d; 4c, d, e, f

RA-8

RA

Female

White

20

+

Etanercept, prednisone

FITDP

1a, b; 2a, b

RA-9

RA

Female

White

21

+

Leflunomide, etanercept, prednisone

FITDP

1a, b; 4a, b; 5a, b, c; 6a, b

RA-10

RA

Male

White

15

+

NSAID, prednisone, adalimumab

FITDP

2a, b; 3c; 4c, d, e, f, g

RA-11

RA

Female

African American

11

+

Hydroxychloroquine, prednisone

FITDP

2a, b; 3c; 4c, d, e, f, g

RA-12

RA

Male

White

>10

+

Etanercept

FITDP

1a, b; 3c; 4a, b

RA-13

RA

Female

Hispanic

>10

+

Methotrexate, prednisone

FITDP

3a, b, c, d; 4c, d, e, f; 6a, b

RA-14

RA

Female

White

3

+

Prednisone, methotrexate

FITDP

5a, b, c; 6a, b

OA-1

OA

Female

White

12

None

Asterand Bioscience

4c, d, e, f

OA-2

OA

Male

White

16

None

Asterand Bioscience

4c, d, e, f

OA-3

OA

Male

White

25

N/A

None

FITDP

4c, d, e, f

OA-4

OA

Male

White

78

N/A

None

FITDP

4c, d, e, f

  1. DMARD disease-modifying antirheumatic drug, FITDP Feinstein Institute Tissue Donation Program, N/A not available, NSAID non-steroidal anti-inflammatory drug, OA osteoarthritis, RA rheumatoid arthritis, RF rheumatoid factor
  2. Patients with RA were 58 ± 10 years old, and patients with OA were 57 ± 5 years old
  3. aCross-references to figures in this article displaying which cells were used